Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
March 29 2022 - 8:00AM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, announced today that it will be participating in the
Lytham Partners Spring 2022 Investor Conference, via presentation
and panel discussion:
- Presentation
- April 4, 2022, at
11:00am ET
- Webcast link:
https://wsw.com/webcast/lytham4/dcth/2015593.
- Panel Discussion -
Latest Technologies to Combat Cancer
- April 5, 2022, at
2:00pm ET
- Webcast link:
https://wsw.com/webcast/lytham4/panel3/2266953
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1x1@lythampartners.com or register at
www.lythampartners.com/spring2022invreg.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of metastatic ocular melanoma (mOM), also known as metastatic uveal
melanoma (mUM) and is considered a combination drug and device
product regulated by the United States Food and Drug Administration
(FDA).
In Europe, the PHP system is now regulated as a Class lll
medical device and is approved for sale under the trade name
CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where
it has been used at major medical centers to treat a wide range of
cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024